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Using a DNA-binding gel mobility shift assay, a protein-DNA complex was detected using the rat II insulin 
promoter and a nuclear extract from rat insulinoma cells. This complex was detected using extracts from 
other insulin-producing cell lines but was not found using nuclear extracts from non-insulin-producing pan- 
creatic ell lines or other cell types. Binding of the tissue-specific protein to the labelled promoter fragment 
was effectively competed by both rat and human insulin genes but not by the SV40 TATA box. This protein- 
DNA interaction may be involved in tissue-specific regulation of insulin gene expression. 
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1. INTRODUCTION 
Eukaryotic promoters and enhancers have been 
shown to be composed of a variable number of cis- 
acting elements which serve to regulate ap- 
propriately gene expression, e.g. in a tissue-specific 
manner or in response to signals by hormones or 
other agents [1]. Such sequences generally include 
a TATA box which directs RNA polymerase to the 
transcriptional start site, near upstream regions 
which regulate the frequency of initiation of 
transcription, and enhancer elements which can af- 
fect gene expression over considerable distances in 
either orientation. These cis-acting elements ap- 
pear to be binding sites for nuclear proteins. Some 
are common to many genes such as the binding 
region for SP 1 [2] or CAAT binding transcription 
factor [3] while others are specific to a given gene 
or family of genes such as the octameric sequence 
found in immunoglobulin genes [4-6]. The actual 
number and type of these elements combine to 
efficiently regulate transcription of a particular 
gene. 
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The insulin gene is expressed in a highly tissue- 
specific manner. Unlike most species, rats possess 
two non-allelic insulin genes which are highly 
homologous within the protein coding sequences; 
this homology extends approx. 500 bp upstream 
from the cap site of the messenger RNA [7]. The 
rat insulin I gene, which has lost one of the two in- 
tervening sequences present in the rat insulin II 
gene, is believed to have arisen via an RNA- 
mediated transposition event from a transcript 
which was initiated upstream from the normal in- 
itiation site of the rat insulin II gene [7]. 
In rats, insulin messenger RNA is only present in 
the ~ cells of the pancreas [8]. Furthermore, it has 
been shown that a region of the gene extending ap- 
prox. 300 bp upstream from the transcriptional in- 
itiation site is exposed to DNase I in a 
transplantable insulinoma but not in other rat 
tissues [9], possibly reflecting the interaction of 
this region of the gene with DNA-binding proteins. 
Further studies on tissue-specific expression of 
the rat insulin I gene have shown that DNA can be 
deleted to within 300 bp of the cap site with no ef- 
fect on expression assays, whereas deletions to 
247 bp abolish activity; for the human insulin gene 
deletions can be made to within 258 bp but activity 
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is lost upon deleting sequences to within 168 bp 
[10]. Further experiments demonstrated that se- 
quences between 103 and 249 bp upstream of the 
rat insulin I gene are sufficient, in either orienta- 
tion, to stimulate expression from the herpes 
simplex virus thymidine kinase (TK) gene pro- 
moter in a tissue-specific manner [11]. Other ex- 
periments focusing on tissue specificity have 
involved fusing 660 bp upstream of the rat insulin 
II cap site to the SV40 large T antigen; large T an- 
tigen was found exclusively in the pancreatic fl cells 
of transgenic mice carrying this construct [12]. The 
upstream tissue-specific enhancer has been further 
characterized by DNase I footprinting and con- 
tains binding sites for both tissue-specific and 
general cellular factors [13]. 
To determine whether other sequences con- 
tributed to tissue specificity, DNA extending from 
113 bp upstream to 51 bp downstream of the rat 
insulin I gene fused to the CAT gene, which main- 
tained negligible levels of activity alone, were 
coupled to the MSV enhancer. When transfected 
into cells, this construct maintained a level of ex- 
pression in insulin-producing cells 10-fold higher 
than that obtained in non-insulin-producing cells 
[11]. This was in contrast to the MSV-tK promoter 
construct which was equally active in both cell 
types. This result indicates the presence in this 
region of another sequence which directs tissue- 
specific expression of the insulin gene. Here, we 
demonstrate the tissue-specific binding of pro- 
tein(s) to this promoter region of the rat insulin II 
gene. 
trypsin treatment. Serum was added to inactivate 
the trypsin and cells were separated from the 
microcarriers by filtration through a CeIlector ap- 
paratus (EC Apparatus). Nuclear extracts were 
prepared following the method of Dignan et al. 
[14]. Briefly, cells were collected by centrifugation, 
resuspended and incubated in hypotonic buffer 
and lysed by homogenization. The nuclei were col- 
lected by centrifugation, washed several times in 
hypotonic buffer, resuspended in a high-salt buffer 
(0.42 M NaCI) and placed on a rotating apparatus 
for 60 min. The suspension was centrifuged and 
the supernatant fraction dialyzed against low-salt 
buffer. Higher salt concentrations did not improve 
extraction of binding proteins as determined by the 
gel mobility shift assay. 
2.2. DNA binding 
DNA binding was carried out at room 
temperature for 30 min in a 20/~1 reaction volume 
containing 10/zg poly(dI-dC) (Pharmacia), 20/zg 
nuclear extract protein, 10000 cpm (-0.5 ng) 32p_ 
labelled insulin promoter fragment (DNA was 
labelled using T4 polynucleotide kinase and 
[T)2p]ATP (Amersham, 5000 Ci/mmol)), 10 mM 
Hepes, pH 7.9, 100 mM KCI, 10070 glycerol, 
0.1 mM EDTA, and 0.25 mM DTT [15]. Where 
indicated, 0.5/zg competitor DNA was included. 
Bromphenol blue was added to the reaction mix- 
tures which were loaded onto pre-electrophoresed 
4.007o polyacrylamide gels. Electrophoresis was 
carried out at 10 V/cm in 40 mM Tris-borate, 
1 mM EDTA for 2 h [16-18]. 
2. MATERIALS AND METHODS 
2.1. Cells and nuclear extracts 
RINm5F, RIND8 and MSLG2 cells were grown 
in RPMI and 1640 media supplemented with 10o70 
fetal calf serum, 50/zg/ml gentamicin and 
2.5/~g/ml amphotericin B. HepG2 cells were 
grown in DME plus 10070 fetal calf serum plus an- 
tibiotics. P388D1 cells were grown in DME plus 
20°70 fetal calf serum, antibiotics and 25 mM 
Mops, pH 7.0. HIT cells were grown in Ham's F12 
nutrient media containing 18% horse serum, 3°70 
fetal calf serum and antibiotics. To prepare 
nuclear extracts, cells were grown in spinner flasks 
containing Cytodex 3 microcarriers (Pharmacia). 
Cells were removed from the microcarriers by mild 
3. RESULTS 
The binding of proteins which may be involved 
in regulation of expression to the insulin promoter 
was examined using the DNA-binding gel mobility 
shift assay [16-18]. The fragment of the rat insulin 
II gene used in these studies is shown in fig. 1 and 
encompasses nucleotides -86 to + 47, relative to 
the site of transcription i itiation (nucleotide +1). 
The 3'-end is located just within the first intron 
located in the untranslated region of the messenger 
RNA. Upon incubating this labelled DNA frag- 
ment with a nuclear extract made from rat in- 
sulinoma cells, Rinm5F, the gel mobility shift 
assay revealed a single major band shifted upward 
from the free DNA indicating the interaction of 
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protein(s) with the DNA (fig.2). On longer ex- 
posure, several minor bands representing other 
DNA-protein interactions were also seen (not 
shown). Increasing the amount of non-specific 
DNA in the binding reaction did not interfere with 
binding indicating that the binding reflects a 
specific interaction with sequences in the rat II in- 
sulin promoter. 
To determine whether this factor might be a 
general cellular factor present in all cell types or a 
TATA 
i ~ , 
-86  0 +47 
Fig.1. The rat insulin II promoter fragment used to 
study protein binding. Numbers are distances in 
nucleotides relative to the site of transcription i itiation 
indicated by the arrow. 
t 
Fig.2. A nuclear protein binds to the insulin gene 
promoter. The end-labelled fragment shown in fig. 1 was 
incubated in the absence (lane 1) or presence (lane 2) of 
a nuclear extract from rat insulinoma (RinmSF) cells as 
described in section 2. 
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tissue-specific protein, nuclear extracts were 
prepared from a variety of cell lines and examined 
for the presence of proteins able to bind to the in- 
sulin promoter (fig.3). The protein-DNA complex 
seen with the RINm5F cell extracts was also seen in 
other insulin-producing cells such as the hamster 
insulinoma, HIT,  cells (lane 7) and a clonally 
selected rat insulinoma cell line, RIND 8 (lane 3). 
However, no interaction was seen using nuclear ex- 
tracts from non-insulin-producing cell types such 
as a hepatoma cell line (Hep G2) (lane 4) or a 
macrophage cell line (P388D1) (lane 5). Further- 
more, the interaction was not seen with extracts 
from MSLG2 cells (lane 6), a transplantable in- 
sulinoma which does not produce insulin in culture 
but which has restored insulin production when 
passaged in rats I19], or with extracts from an 
RIN5F cell line which had been passaged extensive- 
ly in culture and no longer produced insulin (not 
shown). 
Since the formation of the protein-DNA com- 
plex was not only tissue specific but localized to 
cells actively expressing insulin, competition ex- 
periments were performed to determine whether 
the binding was specific to the insulin promoter or 
Fig.3. Binding of a nuclear factor to the insulin gene 
promoter is tissue-specific. The end-labelled insulin 
promoter fragment was incubated with nuclear extracts 
from the following cells: none (lane 1), Rinm5F (lane 2), 
RinD8 (lane 3), HepG2 (lane 4), P388DI (lane 5), 
MSLG2 (lane 6), or HIT (lane 7). 
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could interact with other promoters (fig.4). For 
these experiments, a large excess of unlabelled 
putative competitor DNA was included in the 
binding reaction. Inclusion of pBR322 DNA had 
no effect on binding (not shown). The free DNA is 
shown in lane 1 and control binding with no added 
competitor is shown in lane 4. When plasmids con- 
taining either the rat II insulin promoter (lane 2) or 
the entire human insulin gene (lane 3) were includ- 
ed in the binding reaction, the unlabelled DNA 
competed effectively for binding of the protein(s) 
involved in the complex. The plasmid pA10CAT2 
[201 which contains the SV40 TATA box and the 
21 bp repeats containing the SP1 binding sites at- 
tached to the CAT gene did not compete for 
binding (lane 5). The plasmid pSV2neo [21], which 
contains the SV40 TATA box, 21 bp repeats and 
enhancer coupled to the neomycin resistance gene, 
competed slightly (lane 6) but to a much lesser ex- 
tent than DNA containing the insulin promoter. 
4. DISCUSSION 
The DNA-binding gel mobility shift assay pro- 
Fig.4. Competition analysis of protein binding by other 
DNAs. The free DNA probe is shown in lane 1. The 
binding reactions included the following DNAs as 
competitors: rat insulin promoter (lane 2), human 
insulin gene (lane 3), none (lane 4), pAIoCAT2 (lane 5), 
or pSVEneo (lane 6). 
vides a useful method for analyzing protein-DNA 
interactions using unfractionated nuclear extracts. 
By including varying amounts of non-specific 
DNA in the binding reactions, conditions may be 
established such that specific protein-DNA com- 
plexes are resolved from non-specific interactions. 
Care must be taken in interpreting the results of 
footprinting experiments in which these conditions 
have not been determined. Using this technique, 
we have demonstrated the presence of a protein(s) 
able to bind to the rat insulin II promoter in 
insulin-producing cells. This factor is either not 
present in non-insulin-producing cell lines or is 
modified in some way that renders it unable to 
bind to DNA. The absence of binding not only in 
other cell types but also in insulinoma cells which 
have lost the ability to express insulin suggests that 
this factor may play a role in insulin gene expres- 
sion. Furthermore, the lack of competition by the 
SV40 21 bp repeats and TATA box indicates that 
the factor does not bind to any promoter sequence 
such as a TATA box binding factor [22]. It may in 
fact be specific to the insulin gene but this conclu- 
sion cannot be made without further experimenta- 
tion. The fact that the presence of the SV40 
enhancer esulted in a slight competition may in- 
dicate the presence of a partially homologous e- 
quence or a weak binding site for this factor. In 
addition to competition by the rat insulin II pro- 
moter, the human insulin gene was also an effec- 
tive competitor. Since 30070 of the proximal 
promoter sequence in the human gene is non- 
homologous to the rat insulin II gene [7], this may 
indicate that the binding sequence has been con- 
served during evolution as would be expected for 
a sequence with an important role in regulation of 
insulin gene transcription. 
The presence of a sequence within the insulin 
gene promoter to which proteins bind in a tissue- 
specific manner is of great interest. It has been 
demonstrated that insulin gene transcription is 
controlled by two distinct sequences [11]. The first 
is a tissue-specific enhancer-like lement located 
between - 103 and - 249 nucleotides upstream. 
The second element is located in the promoter 
region studied in this report and leads to cell- 
specific expression when coupled to non-cell- 
specific enhancers. Efficient tissue-specific regula- 
tion may be achieved by interaction between these 
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two sites. This is apparently true for the other 
tissue-specific genes. The mouse prealbumin gene 
also contains two distinct tissue-specific control 
elements; as is the case for the insulin gene, these 
are a promoter sequence and a far upstream 
enhancer-like element [23]. The promoter sequence 
only allows transcription i  hepatoma cells even in 
the presence of a non-specific enhancer, and the 
prealbumin enhancer stimulates expression from a 
heterologous promoter only in hepatoma cells. 
Similarly, immunoglobulin genes possess both a 
cell-specific enhancer and a cell-specific promoter 
[5]. The light chain enhancer stimulates its own 
promoter about 20-fold more than a heterologous 
one [24]. Similar results are seen for the heavy 
chain promoter and enhancer, and both enhancers 
stimulate their own promoters to a greater extent 
than their effect on heterologous promoters. This 
may in fact be of more general occurrence but has 
escaped notice, since many studies on enhancer ac- 
tivity use heterologous promoters and fail to com- 
pare the activity achieved with that obtained using 
the homologous promoter. 
An attractive rationale for having two distinct 
areas governing tissue-specific expression could be 
the tissue-specific binding of proteins to each of 
the areas followed by an interaction between these 
proteins leading to enhanced transcription. Such a 
situation would dictate a tighter control on tissue- 
specific expression. It is very likely that such a 
situation exists for the insulin gene. It has been 
demonstrated previously that both the enhancer 
and promoter of the insulin gene act in a tissue- 
specific manner [11] and, with the results reported 
here, it has been shown that proteins bind in a 
tissue-specific manner to both the enhancer [13] 
and the promoter. Additional experiments to 
determine the precise sequences involved in the in- 
teraction described here, followed by a functional 
assay, are required before it can be conclusively 
stated that this protein-DNA interaction par- 
ticipates in the tissue-specific regulation of insulin 
gene expression. 
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